Clinician’s Guide to Prevention and Treatment of Osteoporosis
Open accessThe DOI matches its Crossref record; 101 of the 102 references it cites were found in a registry or an index; 41 of the 169 sources its claims cite were checked for support.
Abstract
The Clinician's Guide to Prevention and Treatment of Osteoporosis was developed by an expert committee of the National Osteoporosis Foundation (NOF) in collaboration with a multispecialty council of medical experts in the field of bone health convened by NOF. Readers are urged to consult current prescribing information on any drug, device, or procedure discussed in this publication.
Overview
CoChat Summary
TL;DR
This NOF Clinician’s Guide provides recommendations for prevention, risk assessment, diagnosis, and treatment of osteoporosis in postmenopausal women and men age 50 and older, including BMD testing, vertebral imaging, FRAX-based intervention thresholds, and FDA-approved pharmacotherapy. It emphasizes that osteoporosis is common, underdiagnosed, and treatable, with treatment thresholds and drug-specific fracture risk reductions summarized.
Key findings
- Osteoporosis affects more than 9.9 million Americans, with an additional 43.1 million having low bone density; about 1 in 2 Caucasian women and approximately 1 in 5 men will experience an osteoporosis-related fracture. Annually, 2 million fractures are attributed to osteoporosis, causing more than 432,000 hospital admissions, almost 2.5 million medical office visits, and about 180,000 nursing home admissions; costs are expected to rise to $25.3 billion by 2025. Only 23% of women age 67 or older who have an osteoporosis-related fracture receive either a BMD test or a prescription for osteoporosis drug in the 6 months after fracture.
- Pharmacologic treatment is recommended for hip or vertebral fracture, T-score ≤−2.5 at the femoral neck, total hip, or lumbar spine, or low bone mass (T-score between −1.0 and −2.5) with a 10-year hip fracture probability ≥3% or a 10-year major osteoporosis-related fracture probability ≥20% by US-adapted FRAX.
- Universal recommendations include calcium intake of 1000 mg/day for men 50–70 and 1200 mg/day for women 51 and older and men 71 and older; vitamin D 800–1000 IU/day for adults age 50 and older; regular weight-bearing and muscle-strengthening exercise; fall risk assessment and modification; smoking cessation; and avoidance of excessive alcohol.
- Selected drug efficacy data: alendronate reduces spine and hip fractures by about 50% over 3 years; zoledronic acid reduces vertebral fractures by 70%, hip fractures by 41%, and nonvertebral fractures by 25% over 3 years; denosumab reduces vertebral fractures by about 68%, hip fractures by about 40%, and nonvertebral fractures by about 20% over 3 years; teriparatide reduces vertebral fractures by about 65% and nonvertebral fragility fractures by about 53%; raloxifene reduces vertebral fractures by about 30% with prior vertebral fracture and about 55% without; calcitonin reduces vertebral fracture occurrence by about 30% but has not been shown to reduce nonvertebral fractures; ibandronate reduces vertebral fractures by about 50% but nonvertebral fracture reduction has not been documented.
Methods
- Design: guideline developed by an expert committee of the National Osteoporosis Foundation in collaboration with a multispecialty council of medical experts in bone health; recommendations apply to postmenopausal women and men age 50 and older.
- Data or sample: no primary study sample; the Guide synthesizes evidence including NHANES III prevalence estimates, the Women’s Health Initiative, FDA prescribing information, WHO FRAX, and cost-effectiveness analyses.
- Main analysis: expert consensus and evidence synthesis; absolute risk thresholds for pharmacologic intervention were guided by a cost-effectiveness analysis; diagnostic assessment uses central DXA, vertebral imaging, and US-adapted WHO FRAX.
Limitations
- Stated: FRAX underestimates fracture risk in patients with recent fractures, multiple osteoporosis-related fractures, and increased fall risk; it has not been validated for lumbar spine BMD, is not intended for younger adults or children, and has not been validated in patients currently or previously treated with osteoporosis pharmacotherapy.
- Stated: evidence of efficacy beyond 5 years is limited; rare safety concerns such as osteonecrosis of the jaw and atypical femur fractures become more common beyond 5 years; there are relatively few data confirming fracture risk reductions with pharmacotherapy in patients selected by low bone mass plus FRAX thresholds; fracture data are limited in glucocorticoid-induced osteoporosis and in men; and in the absence of head-to-head trials, direct comparisons of risk reduction among drugs should be avoided.
- Evident: the text does not report a systematic search strategy or formal evidence-grading system; the therapeutic thresholds are described as clinical guidance only and “not rules,” requiring individualized clinical judgment.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures
![Fig. 1 Micrographs of normal vs. osteoporotic bone [9], from Dempster et al., with permission of The American Society for Bone and Mineral Research [9]](https://figures.cochat.ai/paper-figures/d609b75c87444980afa9b5aebc701061/clinicians-guide-to-prevention-and-treatment-of-osteoporosis-figure-1.jpg)
![Fig. 2 Pathogenesis of osteoporosis-related fractures, from Cooper and Melton, with modification [10]](https://figures.cochat.ai/paper-figures/ff3ff2f3f4b84a5bbd00a8cc79080d62/clinicians-guide-to-prevention-and-treatment-of-osteoporosis-figure-2.jpg)

Verification
Claims the paper makes
29 Valid · 18 Not valid · 68 Not checked · 17 Own results and interpretations
Some cited sources support this claim and some don’t — read each source’s verdict below.
In the paper
“Raloxifene is also indicated for the reduction in risk of invasive breast cancer in postmenopausal women with osteoporosis [83–86].”
§ Clinician’s Guide to Prevention and Treatment of Osteoporosis > Pharmacologic therapy > Estrogen agonist/antagonist (formerly known as SERMs): Raloxifene
What the sources say
- Not checked — no full text of the sourcecites [83] Cauley JA Norton L Lippman ME Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4-year results from the MORE trial. Multiple outcomes of raloxifene evaluation Breast Cancer Res Treat 2001 65 2 125 134 10.1023/A:1006478317173 11261828 source
- Disputedcites [84] Martino S Cauley JA Barrett-Connor E CORE Investigators Continuing outcomes relevant to Evista: breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene J Natl Cancer Inst 2004 96 23 1751 1761 10.1093/jnci/djh319 15572757 sourceExperimental — accuracy not yet measured
The introduction (p. 1) says raloxifene was approved for preventing and treating postmenopausal osteoporosis, while tamoxifen was the only agent approved in the United States to reduce breast cancer incidence. Although the CORE results (p. 5) show reduced invasive breast cancer incidence with raloxifene, they do not support the claim that breast cancer risk reduction was an approved indication. (LLM, conf=0.88)
Checked by a reasoning model — may be wrong.
- Not checked — no full text of the sourcecites [85] Vogel VG Costantino JP Wickerham DL National Surgical Adjuvent Breast and Bowel Project (NSABP) Effects of tamoxifen vs. raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial JAMA 2006 295 23 2727 2741 10.1001/jama.295.23.joc60074 16754727 source
- Partly supportedcites [86] Barrett-Connor E Mosca L Collins P Raloxifene Use for The Heart (RUTH) Trial Investigators Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women N Engl J Med 2006 355 2 125 137 10.1056/NEJMoa062462 16837676 sourceExperimental — accuracy not yet measured
The Primary Outcomes (p. 5) report that raloxifene reduced invasive breast cancer in the RUTH trial, and the introductory text (p. 2) reports a similar finding from MORE, an osteoporosis-treatment trial. The paper does not state that breast-cancer risk reduction is an approved indication for postmenopausal women with osteoporosis; RUTH enrolled women with or at increased risk for coronary heart disease. (LLM, conf=0.84)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
At least one cited source doesn’t support this claim or points to a different paper, and none confirmed it — see the verdicts below.
In the paper
“Ibandronate reduces the incidence of vertebral fractures by about 50 % over 3 years, but reduction in risk of nonvertebral fracture with ibandronate has not been documented [50].”
§ Clinician’s Guide to Prevention and Treatment of Osteoporosis > Pharmacologic therapy > Bisphosphonates
What the sources say
- Disputedcites [50] Chesnut CH 3rd Skag A Christiansen C Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis J Bone Miner Res 2004 19 18 1241 1249 10.1359/JBMR.040325 15231010 sourceExperimental — accuracy not yet measured
The Clinical osteoporotic nonvertebral fractures section reports a statistically significant 69% reduction with daily ibandronate in women with a baseline femoral-neck BMD T score below −3.0. The Discussion cautions that this was a post hoc analysis and says there was no significant reduction in the overall population, but the unqualified claim that a reduction has not been documented overlooks the reported subgroup finding. Page numbers were not provided in the supplied passages. (LLM, conf=0.88)
Checked by a reasoning model — may be wrong.
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Disputed
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“A vertebral fracture is consistent with a diagnosis of osteoporosis, even in the absence of a bone density diagnosis, and is an indication for pharmacologic treatment with osteoporosis medication to reduce subsequent fracture risk [18, 21].”
§ Clinician’s Guide to Prevention and Treatment of Osteoporosis > Approach to the diagnosis and management of osteoporosis > Vertebral imaging
What the sources say
- Not checked — no full text of the sourcecites [18] Kanis JA Melton LJ 3rd Christiansen C Johnston CC Khaltaev N The diagnosis of osteoporosis J Bone Miner Res 1994 9 8 1137 1141 10.1002/jbmr.5650090802 7976495 source
- Supportedcites [21] Melton LJ Chrischilles EA Cooper C Lane AW Riggs BL How many women have osteoporosis? J Bone Miner Res 2005 20 5 886 892 10.1359/jbmr.2005.20.5.886 15931736 source
The conclusion (OSTEOPENIA, p. 6) distinguishes osteoporosis assessed by bone mineral measurements from established osteoporosis assessed by the occurrence of specific fractures. The introduction (p. 2) identifies vertebral fractures among the principal osteoporosis-related fractures, supporting the stated diagnosis without a bone-density diagnosis. (LLM, conf=0.91)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Help determine adequacy of patient compliance and persistence with osteoporosis therapy”
§ Clinician’s Guide to Prevention and Treatment of Osteoporosis > Approach to the diagnosis and management of osteoporosis > Biochemical markers of bone turnover
What the sources say
- Partly supportedcites [25] Burch J Rice S Yang H Neilson A Stirk L Francis R Holloway P Selby P Craig D Systematic review of the use of bone turnover markers for monitoring the response to osteoporosis treatment: the secondary prevention of fractures, and primary prevention of fractures in high-risk groups Health Technol Assess (Winchester, England) 2014 18 11 1 206 PMC4781229 24534414 sourceExperimental — accuracy not yet measured
The review’s “Compliance and persistence” section describes a model in which a bone turnover marker result could lead to a conclusion that compliance or treatment response was inadequate, but notes that the model did not include test-accuracy data. “Measures of adherence” says that a marker-identified non-response could reflect non-compliance or non-persistence, among several other causes. The source therefore supports markers as a possible clue, not as a way to determine the adequacy of both compliance and persistence. (LLM, conf=0.83)
hedgedstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Predict magnitude of BMD increases with FDA-approved therapies”
§ Clinician’s Guide to Prevention and Treatment of Osteoporosis > Approach to the diagnosis and management of osteoporosis > Biochemical markers of bone turnover
What the sources say
- Partly supportedcites [25] Burch J Rice S Yang H Neilson A Stirk L Francis R Holloway P Selby P Craig D Systematic review of the use of bone turnover markers for monitoring the response to osteoporosis treatment: the secondary prevention of fractures, and primary prevention of fractures in high-risk groups Health Technol Assess (Winchester, England) 2014 18 11 1 206 PMC4781229 24534414 sourceExperimental — accuracy not yet measured
The Clinical Effectiveness and Cost-Effectiveness Evidence section reports correlations between changes in bone turnover markers and BMD, including a statistically significant but weak correlation during teriparatide treatment. It also says not all correlations were significant and cautions that their usefulness varies by population. The review does not establish that markers predict the magnitude of BMD increases across FDA-approved therapies generally. (LLM, conf=0.84)
plainstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
87 more claims · 25 with their cited sources checked
Create a free account to see all 132 claims and to verify the 18 references still open.
- Probably not a substantial claim. 26
- It may state two separate claims as one. 25
- The quote only partly states this claim. 1
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“this equated to a health care cost of $1088”
From Accuracy requirements for cost-effective suicide risk prediction among primary care patients in the US (2021) · cites this paper as [31]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Previous studies31,46,47,48 in emergency department patients have identified primarily benefits, including reductions in health care costs, medical retirement, and depressive symptoms.”
From Accuracy requirements for cost-effective suicide risk prediction among primary care patients in the US (2021) · cites this paper as [31]
Experimental — accuracy not yet measuredIn the citing paper
“yielding an uptake of 89.9%”
From Accuracy requirements for cost-effective suicide risk prediction among primary care patients in the US (2021) · cites this paper as [31]
In the citing paper
“this issue was addressed by instead performing a thorough cost accounting from 2 specific exemplar interventions.30,31”
From Accuracy requirements for cost-effective suicide risk prediction among primary care patients in the US (2021) · cites this paper as [31]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Clinician’s Guide to Prevention and Treatment of Osteoporosis > Approach to the diagnosis and management of osteoporosis > Diagnostic assessment
“Screening BMD and vertebral imaging recommendations for men are outlined in Table 8.”
§ Clinician’s Guide to Prevention and Treatment of Osteoporosis > Approach to the diagnosis and management of osteoporosis > Additional bone densitometry technologies
“Table: Table 8 Additional bone densitometry technologies”
Citations
Cites
Writing Group for the Women's Health Initiative Investigators (2002) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.288.3.321 · Cited by 15,889
Neer, R. M., Arnaud, C. D., Zanchetta, J. R., Prince, R., Gaich, G. A., Reginster, J.-Y., Hodsman, A. B., Eriksen, E. F., Ish-Shalom, S., Genant, H. K., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200105103441904 · Cited by 4,602
Incidence and Economic Burden of Osteoporosis-Related Fractures in the United States, 2005–2025
Burge, R., Dawson-Hughes, B., Solomon, D. H., Wong, J. B., King, A., & Tosteson, A. (2007) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.061113 · Cited by 4,026
Interventions for preventing falls in older people living in the community
Gillespie, L. D., Robertson, M. C., Gillespie, W. J., Sherrington, C., Gates, S., Clemson, L., & Lamb, S. E. (2012) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd007146.pub3 · Cited by 3,966
Professor Kanis, J. A., Melton, L. J., Christiansen, C., Johnston, C. C., & Khaltaev, N. (1994) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.5650090802 · Cited by 3,849
Black, D. M., Cummings, S. R., Karpf, D. B., Cauley, J. A., Thompson, D. E., Nevitt, M. C., Bauer, D. C., Genant, H. K., Haskell, W. L., Marcus, R., et al. (1996) · The Lancet · doi:10.1016/s0140-6736(96)07088-2 · Cited by 3,846
Denosumab for Prevention of Fractures in Postmenopausal Women with Osteoporosis
Cummings, S. R., Martin, J. S., McClung, M. R., Siris, E. S., Eastell, R., Reid, I. R., Delmas, P., Zoog, H. B., Austin, M., Wang, A., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0809493 · Cited by 3,489 · cited 1×
“by about 40 %, and nonvertebral fractures by about 20 % over 3 years [56].”
BackgroundDecreased bioavailability of vitamin D in obesity
Wortsman, J., Matsuoka, L. Y., Chen, T. C., Lu, Z., & Holick, M. F. (2000) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/72.3.690 · Cited by 3,204 · cited 1×
“This regimen should be followed by maintenance therapy of 1500–2000 IU/day or whatever dose is needed to maintain the target blood level [37, 38].”
Background
Research works printed but not linked: 4
- Office of the Surgeon General (US) (2004) Bone health and osteoporosis: a report of the Surgeon General. Office of the Surgeon General (US), Rockville (MD). Available from: http://www.ncbi.nlm.nih.gov/books/NBK45513/. Accessed March 2014 20945569
- National Osteoporosis Foundation Physician’s guide to prevention and treatment of osteoporosis 2005 Washington, DC National Osteoporosis Foundation
- Institute of Medicine (US) Committee to review dietary reference intakes for vitamin D and calcium (2011). In: Ross AC, Taylor CL, Yaktine AL et al (eds) Dietary reference intakes for calcium and vitamin D. National Academies Press (US), Washington (DC). Available from: http://www.ncbi.nlm.nih.gov/books/NBK56070/. Accessed March 2014 21796828
- Cummings, SR, San Martin J, McClung MR et al (2009) FREEDOM Trial. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med 361(8):756–765. (Erratum in: N Engl J Med. 2009;36(10):191) 19671655 · DOI · Paper page
Cited by
Items 2,701–2,800 of 4,108
Osteoporosis in Systemic Autoinflammatory Diseases: A Case-Control Study
Bindoli, S., Franceschet, G., Galozzi, P., Zaninotto, M., Camozzi, V., & Sfriso, P. (2019) · Frontiers in Endocrinology · doi:10.3389/fendo.2019.00636 · Cited by 3
“An increased FRAX R © score for major osteoporotic fractures was detected in SAIDs patients compared to controls, although it is not higher than 20% which is the threshold value recommended by the National Osteoporosis Foundation Guide (10) (Table 4).”
BackgroundHsu, C., Wu, C., Yu, S.-F., Su, Y., Chiu, W.-C., Chen, Y., Lai, H., Chen, J., Ko, C.-H., Chen, J., et al. (2019) · Journal of Bone and Mineral Metabolism · doi:10.1007/s00774-019-01046-4 · Cited by 3
Fracture risk assessment in the general population in Spain by FRAX® algorithm. EPISER2016 study
Gómez‐Vaquero, C., Fábregas-Canales, D., Seoane‐Mato, D., Sánchez‐Piedra, C., Díaz‐González, F., & Bustabad, S. (2020) · Medicina Clínica (English Edition) · doi:10.1016/j.medcle.2019.05.016 · Cited by 3
Jia, K. Q., Southerland, L. T., Phieffer, L. S., Stephens, J. A., & Ing, S. W. (2020) · Aging Clinical and Experimental Research · doi:10.1007/s40520-020-01486-3 · Cited by 4
Osteoporosis Risk Prediction Among a Group of Postmenopausal Females: A Case-Control Study
Mowafy, M. A. (2019) · The Egyptian Family Medicine Journal/The Egyptian Family Medicine Journal · doi:10.21608/efmj.2019.70442 · Cited by 3
Determinants of Bone Mineral Screening Behavior among Three Ethno-Cultural Groups of Women in Israel
Edelstein, O. E., Achdut, N., Vered, I., & Sarid, O. (2020) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph17176138 · Cited by 4
Ayubcha, C., Raynor, W., Borja, A. J., et al. (2020) · Nuclear Medicine Communications · doi:10.1097/mnm.0000000000001344 · Cited by 3
Radeva, M., Predel, D., Winzler, S., Teichgräber, U. K.-M., Pfeil, A., Malich, A., & Papageorgiou, I. E. (2021) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph18031136 · Cited by 3
“well as by the NOF therapeutic recommendations on OP [3].”
BackgroundMethodInfluentialTempleton, K. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-816569-0.00010-3 · Cited by 5
Важаевич, Ц. А., Rodionova, S. S., Sp, M., Сергеевич, Г. Д., & Taraskin, A. Y. (2020) · N N Priorov Journal of Traumatology and Orthopedics · doi:10.17816/vto52895 · Cited by 3
Seaman, A. T., Steffen, M. J. A., Tiem, J. M. V., Wardyn, S. E., Santana, X., Miller, K. L., & Solimeo, S. L. (2021) · Osteoporosis International · doi:10.1007/s00198-021-06098-9 · Cited by 4
The application of FRAX in Ecuador
Gavilánez, E. L., Johansson, H., Harvey, N. C., et al. (2021) · Revista Colombiana de Reumatología · doi:10.1016/j.rcreu.2021.07.004 · Cited by 3
Pharmacokinetic Drug Interaction Between Raloxifene and Cholecalciferol in Healthy Volunteers
Lee, H. W., Kang, W. Y., Jung, W., Gwon, M., Cho, K., Lee, B., Seong, S. J., & Yoon, Y. (2022) · Clinical Pharmacology in Drug Development · doi:10.1002/cpdd.1062 · Cited by 3
Evaluation of Bone Fragility and Fracture Prevention
Pignolo, R. J., & Mukaddam, M. A. (2018) · Springer eBooks · doi:10.1007/978-3-319-72228-3_17 · Cited by 3
Falls and fracture risk assessment—The role of osteoporosis, obesity, and sarcopenia
Sharda, N. K., & Colon-Emeric, C. S. (2022) · Elsevier eBooks · doi:10.1016/b978-0-12-820088-9.00004-4 · Cited by 5
Brandi, M. L., & Medio, L. D. (2020) · Endocrinology · doi:10.1007/978-3-030-14782-2_19 · Cited by 3
Predictors of osteoporosis prevention behaviors in women in their 20s and 30s
Kang, S., & Kim, Y. A. (2022) · Medicine · doi:10.1097/md.0000000000029260 · Cited by 4
“[8,9] Peak bone mass is reached between the age of 20 and early 30s and is maintained until 35 to 40 years of age, after which bone mass begins to decline.[10] Furthermore, an increase in peak bone mass in early adulthood reduces the risk of fracture in older adults,[11] further highlighting the importance of a modifi…”
BackgroundFarhan, L. O., Farhan, A. M., Obaidi, S. A., & Taha, E. M. (2022) · Research Journal of Pharmacy and Technology · doi:10.52711/0974-360x.2022.00444 · Cited by 7
Saber, H. G., & Aly, M. A. E. G. (2022) · Archives of Osteoporosis · doi:10.1007/s11657-022-01144-3 · Cited by 3
“All participants were counselled on appropriate lifestyle behaviours to prevent secondary fractures as suggested by the National Osteoporosis Foundation (NOF) guidelines [9], assessed for recurrent fall risk and advised to follow-up with our clinic post-discharge.”
MethodInfluentialKnowledge and health beliefs of elderly women toward osteoporosis in Mansoura, Egypt
El‐Gilany, A. (2018) · Progress in Medical Sciences · doi:10.47363/pms/2018(2)112 · Cited by 3
Fracture risk prediction with FRAX in Slovak postmenopausal women
Némethová, E., Killinger, Z., & Payer, J. (2013) · Open Medicine · doi:10.2478/s11536-013-0205-2 · Cited by 4
Al‐Azzawi, F. (2013) · Women s Health · doi:10.2217/whe.13.16 · Cited by 3
Fragility Fracture Programs: Are They Effective and What Is the Surgeon’s Role?
Bender, J. S., & Meinberg, E. (2014) · Current Osteoporosis Reports · doi:10.1007/s11914-014-0251-y · Cited by 3
Risk Factors, Prevention, and Treatment of Corticosteroid-induced Osteoporosis in Adults
Ruf, K. M., Johnson, N. K., Clifford, T. M., & Smith, K. M. (2008) · Orthopedics · doi:10.3928/01477447-20080801-29 · Cited by 3
Caso clínico a debate: vacaciones terapéuticas: ¿sí o no?
Henríquez, M. S., Romero, M. J. G. D. T., & Malouf, J. (2014) · Revista de Osteoporosis y Metabolismo Mineral · doi:10.4321/s1889-836x2014000200006 · Cited by 4
Postmenopausal osteoporosis treatment and risk of urinary calculus development.
Ganji, M. R. (2013) · Iranian Journal of Kidney Diseases · Cited by 4
The Role of the Immune System in the Development of Osteoporosis and Fracture Risk
Geusens, P., Goldring, S. R., Briot, K., & Roux, C. (2015) · Elsevier eBooks · doi:10.1016/b978-0-12-800571-2.00011-6 · Cited by 3
DIAGNOSIS, TREATMENT AND PREVENTION OF OSTEOPOROSIS IN GENERAL PRACTICE. CLINICAL GUIDELINES
Lesnyak, O. M., & Toroptsova, N. V. (2014) · Russian Family Doctor · doi:10.17816/rfd201444-17 · Cited by 4
Neurologic Disorders Associated with Bone and Joint Disease
Poncelet, A. N., & Rose-Innes, A. P. (2014) · Elsevier eBooks · doi:10.1016/b978-0-12-407710-2.00022-9 · Cited by 3
Bone health among older adults in Taiwan
Wang, W.-J., Kuo, K., Liaw, C., et al. (2017) · Archives of Gerontology and Geriatrics · doi:10.1016/j.archger.2017.01.003 · Cited by 3
RANKL/RANK/OPG Polymorphisms and Heel Quantitative Ultrasound in Young Adults
Correa‐Rodríguez, M., Schmidt‐RioValle, J., & Rueda‐Medina, B. (2017) · Nursing Research · doi:10.1097/nnr.0000000000000202 · Cited by 3
Sale, J. E. M., Cameron, C., Thielke, S. M., Meadows, L. M., & Senior, K. (2017) · Rheumatology International · doi:10.1007/s00296-017-3712-7 · Cited by 3
Causes and Risk Factors of Osteoporosis
Oleson, C. V., & Morina, A. B. (2017) · Springer eBooks · doi:10.1007/978-3-319-45084-1_2 · Cited by 3
Naylor, K. L., Garg, A. X., Kim, S. J., et al. (2016) · Healthcare Quarterly · doi:10.12927/hcq.2016.24691 · Cited by 3
Treatment and Diagnosis of Osteoporosis
Hong, S. (2017) · Journal of the Korean Neurological Association · doi:10.17340/jkna.2017.4.27 · Cited by 3
PAUSE: A Patient-Centric Tool to Support Patient-Provider Engagement on Menopause
Ashkenazy, R., & Peterson, M. E. (2018) · Clinical Medicine Insights Women s Health · doi:10.1177/1179562x18757467 · Cited by 3
Pharmacokinetic Drug Interaction Study of Bazedoxifene and Ibuprofen
McKeand, W. E., Baird-Bellaire, S. J., Ermer, J. C., et al. (2018) · Clinical Pharmacology in Drug Development · doi:10.1002/cpdd.433 · Cited by 3
Parathyroid hormone and abaloparatide treatment for osteoporosis
Cosman, F. (2018) · Current Opinion in Endocrine and Metabolic Research · doi:10.1016/j.coemr.2018.02.005 · Cited by 4
Self-citationExtended Use of Systemic Menopausal Hormone Therapy
Kaunitz, A. M. (2018) · Clinical Obstetrics & Gynecology · doi:10.1097/grf.0000000000000382 · Cited by 3
Prevention of Falls and Fractures - To „D” or Not to „D”?
Grigorie, D., & Sucaliuc, A. (2018) · Acta Endocrinologica (Bucharest) · doi:10.4183/aeb.2018.235 · Cited by 4
Öztürk, N., Öztürk-Işık, E., & Ülgen, Y. (2018) · Journal of Electrical Bioimpedance · doi:10.2478/joeb-2018-0007 · Cited by 3
An In Silico Model for the Prediction of Changes in Mineral Density in Cortical Bone Remodeling
Mattazio, R. R., Noritomi, P. Y., & Silveira, Z. D. C. (2019) · Journal of Biomechanical Engineering · doi:10.1115/1.4044094 · Cited by 3
Joshi, M., Bisht, S., & Singh, M. F. (2019) · International Journal of Pharmacy and Pharmaceutical Sciences · doi:10.22159/ijpps.2019v11i10.34447 · Cited by 5
“Insights are drawn from the scholarly literature the potential risk factors that can predispose to osteoporosis are shown in the table [15, 19].”
BackgroundThe Effect of Body Pump Training on Bone Mineral Density and Balance in Postmenopausal Women
Kakavandi, M. A., Alikhani, S., & Azizbeigi, K. (2019) · ranian Journal of Health Education and Health Promotion · doi:10.29252/ijhehp.7.3.316 · Cited by 3
Moneim, R. A. A., Mostafa, A., & Abbass, M. M. S. (2020) · The Egyptian Journal of Histology · doi:10.21608/ejh.2020.20936.1213 · Cited by 4
“Osteoporosis is a silent disease; manifested only in a low bone density, until fracture occurs[2].”
BackgroundLee, H. J., Hwang, S. Y., Kim, S. C., et al. (2020) · Metabolic Syndrome and Related Disorders · doi:10.1089/met.2019.0060 · Cited by 3
Cabrera, J. A. B., Henríquez, M. S., Díaz Curiel, M., Moliní, P. S., García, F. A., Montoya-García, M.-J., Filgueira, J. S., Olmos, J. M., Coco-Martín, M. B., Castrillón, J. L. P., et al. (2020) · Revista Clínica Española · doi:10.1016/j.rce.2020.06.004 · Cited by 3
Physiotherapy rehabilitation in patients with osteoporosis
Nava, T. (2020) · Journal of Advanced Health Care · doi:10.36017/jahc2003-007 · Cited by 3
Fracture risk assessment in nursing homes
Harvey, N. C., & Cooper, C. C. (2020) · European Geriatric Medicine · doi:10.1007/s41999-020-00384-1 · Cited by 3
Sagalla, N., Colon-Emeric, C. S., Sloane, R. J., Lyles, K. W., Vognsen, J., & Lee, R. S. (2020) · Osteoporosis International · doi:10.1007/s00198-020-05616-5 · Cited by 4
Singer, A. J. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-813073-5.00029-0 · Cited by 3
Evaluation of the osteoporosis patient
Lewiecki, E. M. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-813073-5.00061-7 · Cited by 5
Self-citationEwees, A. A., Elaziz, M. A., Arafa, R. M., & Ghoniem, R. M. (2020) · IEEE Access · doi:10.1109/access.2020.3036831 · Cited by 6
Prevalence and risk of bone fractures in patients with chronic pancreatitis: meta-analysis
Андреев, Д. Н., Maev, I. V., & Kucheryavyy, Y. A. (2021) · Rheumatology Science and Practice · doi:10.47360/1995-4484-2021-56-61 · Cited by 3
Osteoporosis and lifestyle medicine
Mahadik, A. B., Giri, A. B., Bhambre, A. S., Mundhe, S. A., & Shinde, R. D. (2021) · GSC Biological and Pharmaceutical Sciences · doi:10.30574/gscbps.2021.14.2.0054 · Cited by 5
“Certain foods high in phosphorous include nuts, beans, meat, fishes and other dairy products(30).”
BackgroundClinical Usefulness of FRAX Score for Predicting Sarcopenia in Patients with Chronic Liver Disease
Saeki, C., Saito, M., Kanai, T., Nakano, M., Oikawa, T., Torisu, Y., Saruta, M., & Tsubota, A. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10184080 · Cited by 5
“The FRAX score for high risk of osteoporotic fracture was defined as a 10-year major osteoporotic fracture probability ≥20% or a 10-year hip fracture probability ≥3% [16].”
BackgroundAssociation between LEPR polymorphism and susceptibility of osteoporosis in Chinese Mulao people
Ye, G., Yandong, H., Yin, L., et al. (2022) · Artificial Cells Nanomedicine and Biotechnology · doi:10.1080/21691401.2021.2020279 · Cited by 3
“health problem that seriously affects human health [1,2].”
BackgroundValencia, W. M., & Florez, H. J. (2016) · Springer eBooks · doi:10.1007/978-3-319-31831-8_22 · Cited by 3
Evaluation of the tolerability of zoledronic acid preparations for parenteral administration
Шафиева, И. А., Bulgakova, S. V., & Shafieva, A. V. (2022) · Meditsinskiy sovet = Medical Council · doi:10.21518/2079-701x-2022-16-11-96-101 · Cited by 3
Musculoskeletal Development and Skeletal Pathophysiology’s
Bradley, E. W. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23169092 · Cited by 3
“Musculoskeletal (MSK) disorders are one of the leading causes of disability for people of all ages and impart significant socio-economic burdens on society [1,2].”
BackgroundBisphosphonate-induced atypical femoral fracture in tandem: long-term follow-up is warranted
Hussain, M. A., Joseph, A., Cherian, V. M., et al. (2022) · Endocrinology Diabetes and Metabolism Case Reports · doi:10.1530/edm-22-0249 · Cited by 3
“…we summarise the case of a woman who developed AFF on both sides, in tandem, the second fracture occurring 5 years after the discontinuation of BPs. Osteoporosis is a silent disease until fractures occur, and this leads to heightened societal costs with increased morbidity and mortality (4).”
BackgroundKomorbiditet ved marginal parodontitis: To sider af samme sag?
Holmstrup, P., Damgaard, C., Olsen, I., Klinge, B., Flyvbjerg, A., Nielsen, C. H., & Hansen, P. R. (2017) · Den norske tannlegeforenings Tidende · doi:10.56373/2017-1-5 · Cited by 3
Still, C. D., Benotti, P. N., Hangan, D., & Zubair, F. (2018) · Springer eBooks · doi:10.1007/978-3-319-75841-1_2 · Cited by 6
ARE TRAUMATOLOGISTS TREATING OSTEOPOROSIS TO PREVENT NEW FRACTURES IN BRAZIL?
Zamboni, C., Carvalho, M. S., Pires, E. A., et al. (2018) · Acta Ortopédica Brasileira · doi:10.1590/1413-785220182606202125 · Cited by 3
Abnormal bone mineral content and density in people with tetrasomy 18p
Moreira, A., Das, H., Hasi, M., Soileau, B. T., Hill, A., Bruder, J., Hale, D. E., & Cody, J. D. (2019) · American Journal of Medical Genetics Part A · doi:10.1002/ajmg.a.61005 · Cited by 4
Orces, C. H., & Gavilánez, E. L. (2020) · Nutrición Hospitalaria · doi:10.20960/nh.02917 · Cited by 6
Still a Major Concern: Osteoporosis Has a Serious Impact on Quality of Life
Kutsal, Y. G. (2020) · Turkish Journal of Osteoporosis · doi:10.4274/tod.galenos.2020.17136 · Cited by 3
“Health consequences from osteoporotic fractures in patients include disability and have a negative impact on the Quality of Life (QoL) (2-4).”
BackgroundLangsetmo, L., Shikany, J. M., & Rogers-Soeder, T. S. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-813073-5.00021-6 · Cited by 3
Factors Influencing Measures of Trochanteric Soft Tissue Thickness
Lafleur, B. (2016) · UWSpace (University of Waterloo) · Cited by 3
Abstracts of XXII International Scientific and Practical Conference
Ахтоян, А., Король, І. В., Сергієнко, О. А., Суботіна, Ю. О., & Цибко, Н. О. (2021) · doi:10.46299/isg.2021.i.xxii · Cited by 5
Shaik, A., Larsen, K. S., Lane, N. E., et al. (2024) · SSRN Electronic Journal · doi:10.2139/ssrn.4889454 · Cited by 3
AI and Chest Radiographs: A Dawning Era in Osteoporosis Screening
Smith, A. D., & Rothenberg, S. (2024) · Radiology · doi:10.1148/radiol.241339 · Cited by 3
Barreira‐Hernández, D., Rodríguez‐Martín, S., Gil, M., Mazzucchelli, R., Izquierdo-Esteban, L., García‐Lledó, A., Pérez-Gómez, A., Rodríguez-Miguel, A., & de Abajo, F. J. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12165294 · Cited by 2
López, A. A. P., Chávez-Negrete, A., Rodríguez-Lozano, A. L., Gómez-Alarcón, Á. J., Montaño-Velázquez, B. B., Hinojosa, C. A., Sánchez-Hernández, C., Pimentel-Hernández, C., Dehesa-López, E., Romero-Moreno, F., et al. (2026) · Revista Mexicana de Endocrinología Metabolismo y Nutrición · doi:10.24875/rme.m23000030 · Cited by 9
Qian, D., Zhou, H. C., Yang, Q., Liu, Y., Wang, Z., Lu, S., Tong, G., Zhang, L., Wang, X., & Zhou, S. (2024) · International Journal of Pharmacology · doi:10.3923/ijp.2024.229.240 · Cited by 3
Jackson, L. E., Skains, R. M., Mudano, A. S., Techarukpong, N. C., Booth, J. S., Saag, K. G., Fraenkel, L., & Danila, M. I. (2024) · JBMR Plus · doi:10.1093/jbmrpl/ziae038 · Cited by 2
“17 Despite evidence that increased BMD testing, most commonly using dual-energy X-ray absorptiometry (DXA), is associated with greater preventative osteoporosis care, rates of screening are low.”
Yeh, H., Wu, H.-T. H., Shen, H., Li, T., Yang, Y., Lee, K., Lin, Y., Huang, C., & Hou, M. (2024) · Endocrine Connections · doi:10.1530/ec-24-0089 · Cited by 2
“Fractures occurring in a setting of low-level or low-energy trauma, defined as falling from standing height or less, are usually related to osteoporosis (16).”
BackgroundWang, Y., & Yi, P. C. (2024) · World Journal of Clinical Cases · doi:10.12998/wjcc.v12.i19.3908 · Cited by 2
Köhli, P., Hambrecht, J., Zhu, J., Chiapparelli, E. A., Schönnagel, L., Guven, A. E., Duculan, R., Otto, E., Kienzle, A., Evangelisti, G., et al. (2025) · North American Spine Society Journal (NASSJ) · doi:10.1016/j.xnsj.2025.100591 · Cited by 4
Santos, T. A., Ribeiro, J. L., Battistelli, L. S., & Anbinder, A. L. (2025) · Journal of Bone and Mineral Metabolism · doi:10.1007/s00774-025-01600-3 · Cited by 2
“It is a silent disease, rarely showing signs and symptoms until a fracture occurs [2].”
Yang, B., Tan, M., & Xiong, F. (2025) · Medicine · doi:10.1097/md.0000000000042367 · Cited by 3
“[7] Osteoporosis includes primary osteoporosis and secondary osteoporosis.”
Review of Osteoporotic Fractures: Occurrence, Prevention, and Consequences
Elias, N., Ribeiro, J. E. G., Campinho, L. A., Reis, C., Elias, L. A. M. S., & Labronici, P. J. (2025) · Revista Brasileira de Ortopedia · doi:10.1055/s-0044-1789220 · Cited by 14
Dawod, M. S., Alswerki, M. N., Yasin, M. S., Altamimi, A. A., Saber, Y., Alrawashdeh, O., Afifi, T., & Al-Ajlouni, J. M. (2025) · BMC Musculoskeletal Disorders · doi:10.1186/s12891-025-08853-z · Cited by 5
Zhang, J., Lei, C., Mu, G., & Wu, X. (2025) · Journal of Dairy Science · doi:10.3168/jds.2025-26729 · Cited by 3
Yang, Y., Zhou, H., Wang, Y., Ming, Y., Gong, F., Wu, S., Luo, Z., Bi, Z., Xu, J., Chen, Y., et al. (2025) · Phytotherapy Research · doi:10.1002/ptr.8519 · Cited by 2
Özcan, B., Ceylan, S., Özcan, M., Güner, M., Balcı, C., Cankurtaran, M., Halil, M. G., & Doğu, B. B. (2025) · British Journal of Clinical Pharmacology · doi:10.1002/bcp.70243 · Cited by 2
“1,2,12,44,45 Our findings, supported by existing literature, highlight diabetes mellitus as a uniquely impactful factor in OP treatment efficacy due to its disruption of bone remodelling and microfracture repair, which increases fracture risk and suggests a distinct diabetes-related bone disorder.”
Effect of comorbidities and multimorbidity on bone mineral density in patients with osteoporosis
Vega, L. L., Coco-Martín, M. B., Martín-Gutiérrez, A., Blázquez-Cabrera, J. A., Arranz-García, F., Navarro, A., Moro, M. J., Filgueira, J. S., Henríquez, M. S., Vázquez, M. Á., et al. (2025) · Archives of Osteoporosis · doi:10.1007/s11657-025-01604-6 · Cited by 2
“Patients diagnosed with osteoporosis according to the den-sitometric criteria established by the World Health Organization (WHO) (T-score −2.5 at any location) or with typical fragility fractures regardless of BMD were included [15, 16].”
InfluentialMedium-term transition rates to osteoporosis: DXA analysis in older Asians
Vy, V. P. T., Lü, Y., Griffith, J. F., Lin, Y. C., Chan, C., CAREY, J. J., & Chan, W. P. (2025) · Archives of Osteoporosis · doi:10.1007/s11657-025-01605-5 · Cited by 2
“Bone mineral density (BMD) assessment via dual-energy X-ray absorptiometry (DXA) is the gold standard for diagnosing osteoporosis, in the absence of insufficiency fracture [1].”
Tian, Z., Gao, Y., Zhou, B., Fang, Z., Zheng, G., Zhang, H., He, F., Chen, X., Liu, M., Yuan, W., et al. (2025) · Journal of Exercise Science & Fitness · doi:10.1016/j.jesf.2025.09.003 · Cited by 2
Jiang, J., Wu, J., Chen, Y., & Zhou, Y. (2025) · BMC Public Health · doi:10.1186/s12889-025-24364-x · Cited by 5
Evaluating Bone Mass with Opportunistic Chest CT: T8 as the Optimal Vertebral Level
Zheng, H., Li, X., Cai, H., Xiao, W., Zhou, Z., & Zheng, L. (2025) · Calcified Tissue International · doi:10.1007/s00223-025-01445-y · Cited by 3
“Nonetheless, osteoporosis could be diagnosed by the presence of VOF independent of DXA measurements [15, 42].”
Sugawara, Y., Shimizu, T., Ishizu, H., Arita, K., Ohashi, Y., Yamazaki, S., Kokabu, T., Yamada, K., & Iwasaki, N. (2025) · Bone · doi:10.1016/j.bone.2025.117745 · Cited by 3
Associations between dietary index for gut microbiota and bone health outcomes
Hidayat, K., Hong, W., Wang, L.-L., Rizzoli, R., Du, H., Li, D., Li, Z., & Qin, L. (2025) · Osteoporosis International · doi:10.1007/s00198-025-07772-y · Cited by 2
“As BMD serves as a surrogate for bone strength, lower BMD is associated with compromised skeletal integrity and greater fracture risk [5–8].”
Wu, H., Liu, Y., Zhang, J., et al. (2025) · Journal of General Internal Medicine · doi:10.1007/s11606-025-10090-y · Cited by 2
Bugbird, A. R., Burghardt, A. J., Langsetmo, L., Ensrud, K. E., Bouxsein, M., Kiel, D. P., Boyd, S. K., & Whittier, D. E. (2025) · Journal of Bone and Mineral Research · doi:10.1093/jbmr/zjaf187 · Cited by 2
“23, 24, 25, 26 FN aBMD was used as a standalone predictor variable without incorporating clinical risk factors (CRFs) such as age and sex.”
Lu, F., Chen, J., Liu, Z., Xu, C., Yuan, C., Fan, S., Tung, T.-H., Zhang, L., & Hong, D. (2026) · Aging Clinical and Experimental Research · doi:10.1007/s40520-025-03281-4 · Cited by 2
“Secondly, many studies did not formally diag - nose osteoporosis in patients with fragile vertebral fractures, as not all met the T-score threshold [ 11].”
Yang, Z., Tang, R., Ma, Y., Luo, W., & Hu, Y. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1712682 · Cited by 2
“Osteoporosis (OP) is a systemic skeletal disease characterized by reduced bone mass, deterioration of bone microstructure, increased bone fragility, and elevated risk of fractures (Cosman et al., 2014).”
Osteoporosis: definition, diagnosis, and considerations prior to starting treatment
Vidal, M., & Lane, N. E. (2026) · Exploration of Endocrine and Metabolic Diseases · doi:10.37349/eemd.2026.101456 · Cited by 2
Zheng, S., Luo, X., Chen, G., & Wang, P. (2026) · Medicine · doi:10.1097/md.0000000000047356 · Cited by 3
“[6] OP-related fractures are the primary cause of disability and mortality.”
Clark, B. C., Manini, T. M., Simon, J. E., Clark, L. A., Lyssikatos, C., & Warden, S. J. (2026) · Journal of Bone and Mineral Research · doi:10.1093/jbmr/zjag032 · Cited by 3
“For comparison with current clinical practice, we also classified participants using WHO osteoporosis criteria (T-score ≤ − 2.5 at the LS, TH, or FN), 46 and summarized sensitivity and specificity for fracture discrimination.”
Influential
Metadata
- Authors
- Cosman, F., de Beur, S. J., LeBoff, M. S., Lewiecki, E. M., Tanner, B., Randall, S., & Lindsay, R.
- Affiliations
- Helen Hayes Hospital (US)
- Brigham and Women's Hospital (US)
- New Mexico Clinical Research & Osteoporosis Center (US)
- Bone Health and Osteoporosis Foundation (US)
- Corresponding author
- Cosman, F.
- Venue
- Osteoporosis International
- Published
- 2014-08-15
- Volume
- 25
- Issue
- 10
- Pages
- 2359-2381
- ISSN
- 0937-941X (ISSN-L)
- 1433-2965
- PMC
- PMC4176573
- OpenAlex
- W2171709369
- Semantic Scholar
- 91c0d02cdbd4c5dd69ed206e6a0b2b94c9aa0830
- Cited by
- 4,149
- References
- 101
- Citations by year
- 2026: 141 · 2025: 226 · 2024: 267 · 2023: 292 · 2022: 351 · 2021: 415 · 2020: 458 · 2019: 336 · 2018: 311 · 2017: 304 · 2016: 285 · 2015: 246 · 2014: 141
- FWCI
- 242.08
- Type
- journal article
- Language
- en
- Update notices
- correction (2015-05-19)
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Osteoporosis International (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- PubMed Central (submittedVersion, cc-by-nc)
- Topics
- Health Sciences › Medicine › Orthopedics and Sports Medicine › Bone health and osteoporosis research
- Health Sciences › Medicine › Oncology › Bone health and treatments
- Health Sciences › Medicine › Surgery › Hip and Femur Fractures
- Keywords
- osteoporosis, osteoporosis prevention, osteoporosis treatment, bone health, osteoporosis drugs
- MeSH terms
- Aged, Calcium, Dietary, Diet, Female, Humans, Male, Middle Aged, Osteoporosis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-09-30, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-09-30 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.